Skip to main content
Download PDF

GWAS-identified CCR1 and IL10 loci contribute to M1 macrophage-predominant inflammation in Behçet’s disease

Arthritis Research & Therapy volume 20, Article number: 124 (2018) Cite this article

Abstract

Background

Low C-C chemokine receptor 1 (CCR1) and interleukin (IL)-10 expression is associated with risk of Behçet’s disease (BD). The objective of the present study was to clarify the pathological roles of CCR1 and IL10 loci identified by previous BD genome-wide association studies (GWASs).

Methods

M1 and M2 macrophages (Mφ) were differentiated with granulocyte-macrophage colony-stimulating factor or macrophage colony-stimulating factor (M-CSF) from peripheral monocytes of healthy control subjects (HC) and patients with BD. Expression of CD68 and CD163 was evaluated to test for Mφ polarization. CCR1 and IL-10 messenger RNA (mRNA) and protein expression was compared according to CCR1 and IL10 single-nucleotide polymorphism (SNP) genotypes. The migratory ability of M1 and M2 Mφ toward CCR1 ligand macrophage inflammatory protein (MIP)-1α was compared. The ratio of M1 and M2 Mφ in skin lesions of BD and systemic sclerosis (SSc), which was reported to be M2 Mφ-dominant, was compared. To examine the plasticity of polarized Mφ, the differentiated cells were cultured with either the same or the other culture condition.

Results

Preferential expression of CD163, CCR1, and IL-10 was found in M2 Mφ compared with M1 Mφ. M2 Mφ migrated more sensitively to low concentrations of MIP-1α than M1 Mφ did. BD-derived M1 Mφ showed higher CCR1 surface expression than HC-derived M1 Mφ did. IL10 and CCR1 mRNA expression differences were observed by GWAS-identified SNP genotypes in polarized Mφ. BD skin lesions showed M1 Mφ predominance compared with SSc skin lesions. A plasticity assay revealed that M-CSF restored IL-10 synthesis and reduced IL-6 production by M1 Mφ.

Conclusions

The present study reveals that GWAS-identified SNPs contribute to M1 Mφ-predominant inflammation in BD. Our data also suggest that the skewed Mφ polarization is correctable by immunological intervention.

Background

Behçet’s disease (BD) is an idiopathic inflammatory disease that affects multiple organs, including the skin, eyes, vasculum, and mucosa [1, 2]. Genetic factors such as HLA-B*51, as well as environmental factors, including microbial components, have been implicated in the pathogenesis of BD [3]. Recent genome-wide association studies (GWASs) followed by subsequent genetic studies have identified nearly 20 loci as the disease susceptibility genes, most of which are involved in both innate and acquired immune systems [4,5,6,7,8,9,10]. Of them, IL10 and CCR1 are highly expressed genes in macrophages (Mφ). IL-10 is one of the cytokines conferring the anti-inflammatory effect, involved in the pathogenesis of various autoimmune diseases, including systemic lupus erythematosus (SLE) and inflammatory bowel diseases (IBD) [11]. Some studies have shown evidence that IL-10 is increased in BD inflamed tissues [12, 13]. However, genetic studies revealed that a BD risk single-nucleotide polymorphism (SNP) allele is associated with lower interleukin (IL)-10 production [4, 6], implicating complex interaction of T-helper cell Th1, Th2, and Th17 cytokines in BD [14].

CCR1 (C-C chemokine receptor 1), a membrane receptor for chemokines such as macrophage inflammatory protein (MIP)-1α, is known to be expressed on myeloid cells and is involved in cell migration [15]. We previously reported that the disease risk allele of IL10 locus rs1518111 is associated with reduced production of IL-10, as well as of CCR1 locus rs7616215, an SNP in the 3′ noncoding region, and that it is associated with lower CCR1 messenger RNA (mRNA) expression and reduced monocyte chemotaxis [5]. The result was unexpected because the low chemotactic ability of monocytes, which seems to be protective from inflammation, was identified as a risk for BD. This genetic findings do not directly correspond to previous functional studies that have shown excessive production of Mφ-derived proinflammatory cytokines, including tumor necrosis factor (TNF)-α, which is the most effective therapeutic target in BD [16, 17]. Additionally, our recent genetic study suggested that an effective target may be the IL1A–IL1B locus, which is related to enhanced IL-1β production from activated Mφ [10].

Mφ polarization concepts have gained attention, especially in the field of tumor immunity [18]. Further studies have revealed that Mφ are divided into two major subtypes with distinct functions: M1 and M2 Mφ. M1 Mφ are classical Mφ and play a proinflammatory role through the production of IL-6 and TNF-α, and they activate the Th1 cellular immune response, whereas M2 Mφ are nonclassical Mφ which produce anti-inflammatory cytokine IL-10 that suppresses inflammatory responses [19]. The functional and phenotypic diversity of Mφ has been also investigated in physiological and other pathological conditions [20]. Recent GWASs have identified IL10 and related genes as susceptibility genes associated with immune-mediated diseases such as IBD and SLE in addition to BD, suggesting the involvement of abnormal M2 Mφ function in the pathogenesis of these diseases [21]. Indeed, dysfunction of M2 Mφ has been shown to exacerbate inflammation in a herpes simplex virus-induced BD mouse model [22]. We previously revealed that downregulation of heme oxygenase (HO)-1, which is preferentially expressed as an M2 Mφ-specific anti-inflammatory protein, suggested M2 Mφ dysfunction in BD [23]. These findings prompted us to analyze functional studies of Mφ polarization in human patients with BD. The results of the present study support the hypothesis that GWAS-identified CCR1 and IL10 loci contribute to impaired M2 Mφ function, which is partly due to genetic predisposition, and lead to M1 Mφ-predominant immune responses in BD.

Methods

Study subjects

All of the individuals with BD in this study fulfilled the International Study Group (ISG) criteria for BD [24]. The study protocol and genetic analyses were approved by the Yokohama City University Hospital Ethics Board (A140327015 and B131107009). All of the human samples were used after written informed consent was obtained.

Cell preparation and culture

Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Lymphoprep (Axis-Shield, Dundee, UK). Human monocytes were isolated from PBMCs using the Human Monocyte Isolation Kit II magnetic-activated cell sorter (Miltenyi Biotec, Bergisch-Gladbach, Germany) according to the manufacturer’s protocol [23]. Isolated monocytes were plated at a density of 5 × 105 cells/ml and were incubated in RPMI 1640 medium (R8758; Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% FBS (MP Biomedicals, Santa Ana, CA, USA) in the presence of either recombinant 20 ng/ml human granulocyte-macrophage colony-stimulating factor (GM-CSF) (215-GM; R&D Systems, Minneapolis, MN, USA) or 50 ng/ml macrophage colony-stimulating factor (M-CSF) (216-MC; R&D Systems) for 9 days to induce differentiation to M1 or M2 Mφ, respectively [25].

Flow cytometry

Antibodies for CD68 (FITC 333806), CD163 (PE-Cy7 333614), and CCR1 (PE 362904) were purchased from BioLegend (San Diego, CA, USA). Incubation of polarized Mφ with antibodies was performed according to the manufacturer’s protocol. M1 and M2 Mφ were defined as CD68+CD163− and CD68+CD163+ cells, respectively. All the gates were determined using fluorescence minus one control. Data were collected on a BD FACSCanto II instrument (BD Biosciences, San Jose, CA, USA) and analyzed using FlowJo software version 10 (FlowJo, Ashland, OR, USA).

IHC (Immunochemical) staining

Cultured cells were fixed on Nunc Lab-Tek chamber slides (Thermo Fisher Scientific, Waltham, MA, USA) with 4% paraformaldehyde. The slides and paraffinized skin specimens obtained from four patients with BD and four patients with systemic sclerosis (SSc) were deparaffinized in xylene, hydrated in ethanol, and pretreated with 10 mmol/L citrate buffer (pH 6.0). The cells and tissues were used for IHC analysis. Mouse monoclonal anti-CD68 antibody (PGM1; Dako, Carpinteria, CA, USA), anti-CD163 antibody (Leica Biosystems, Berlin, Germany), and rabbit polyclonal immunoglobulin G (IgG) anti-CCR1 antibody (GenWay Biotech, San Diego, CA, USA) at 1:100 dilution were used as primary antibodies. The REAL EnVision Detection System (Dako) was used with secondary antibodies for visualization by light microscopy [26]. To count M1 and M2 Mφ in skin lesions, CD68+ and CD163+ cells were counted in three high-power fields (magnification × 400), and the average CD68/CD163 ratio was obtained in each patient. For double-immunofluorescence staining, Alexa Fluor 555 anti-mouse IgG (Life Technologies, Carlsbad, CA, USA) and Alexa Fluor 488 anti-rabbit IgG (Life Technologies) at 1:500 dilution were used as secondary antibodies. The slides were mounted with 4′,6-diamidino-2-phenylindole (Vector Laboratories, Peterborough, UK) and imaged by fluorescence microscopy.

Semiquantitative mRNA analysis

mRNA was extracted using the RNeasy kit (Qiagen, Hilden, Germany), and complementary DNA (cDNA) was synthesized using the SuperScript III reverse transcriptase (Life Technologies). Primers for real-time PCR of CD163 (Hs00174705_m1), CCR1 (Hs00174298_m1), CCR2 (Hs00704702_s1), IL6 (Hs00174131_m1), and IL10 (Hs00961622_m1) were purchased from Applied Biosystems (Foster City, CA, USA). GAPDH (4310884E) was used as an internal control when performing multiplex PCR. The comparative cycle threshold (2−ΔΔCt) method was used for the analysis of duplicate or triplicate reactions [4].

Measurements of cytokines

Lipopolysaccharide (LPS) from Escherichia coli (serotype 0111:B4; InvivoGen, San Diego, CA, USA) was used at 1 μg/ml. After incubation for 24 hours, the supernatants were centrifuged and stocked at − 80 °C until use. The concentrations of TNF-α, IL-6, and IL-10 were quantified using the BD Bead Assay (BD Biosciences) in accordance with the manufacturer’s protocol.

Migration assay

Transwell migration assay was performed using 5-μm pore polycarbonate membrane (Corning Costar, Kennebunk, ME, USA). M1 and M2 Mφ were cultured on RepCell (CellSeed, Tokyo, Japan) [27]. After detachment of cells incubated at 20 °C for 30 minutes, the cells were used for the following experiments. M1 or M2 Mφ (5 × 104) were applied in the upper chamber. In the lower chamber, 1% bovine serum albumin (Wako Pure Chemical Co., Osaka, Japan)-supplemented RPMI 1640 medium with or without recombinant human MIP-1α (R&D Systems) was applied. After incubation for 2 hours, cells in the upper chamber were removed with Q-Tips, and cells on the bottom side of the membrane were stained with Diff-Quik (Sysmex, Kobe, Japan). Cells were randomly counted in 25 high-power fields. The migration index was defined as the ratio between the migrated cell counts with or without MIP-1α.

Plasticity assay

After a 9-day incubation of monocytes from BD or SSc with GM-CSF or M-CSF, polarized M1 or M2 Mφ were further incubated in the presence of GM-CSF or M-CSF for another 9 days (Fig. 4a). cDNA was obtained after the 18-day incubation.

SNP genotyping

Genomic DNA was isolated with the DNeasy Blood & Tissue Kit (Qiagen) or BuccalQuick (Trimgen, Sparks, MD, USA). A TaqMan SNP genotyping assay was used to identify SNPs associated with expression of IL10 (C___8828803_1_; Applied Biosystems) and CCR1 (C___1198110_10; Applied Biosystems) [4].

Statistical analysis

Student’s unpaired t test was used to test statistical significance. A P value of < 0.05 was considered significant. One-way analysis of variance was performed to compare three groups, except for the groups that did not contain sufficient samples suitable for analysis owing to allelic scarcity. In the latter instance, we combined heterozygous with homozygous minor alleles and analyzed them using an unpaired Student’s t test. Statistical analysis was performed using Prism software (GraphPad Software, La Jolla, CA, USA).

Results

Mφ polarization in human circulating monocytes

First, we tested the Mφ polarization protocol in peripheral monocytes purified from healthy control subjects (HC) according to a description in a previous report [25]. M1 and M2 Mφ differentiation was induced from peripheral monocytes by GM-CSF and M-CSF, respectively. The cultured cells showed distinct morphological features between the two culture systems (Additional file 1: Figure S1A and B). We confirmed that both mRNA and CD163 protein, one of the conventional M2 markers, were elevated in M2- rather than M1-cultured cells (Additional file 1: Figure S1C and D) [28]. Cytokine profiles after 24-h LPS stimulation revealed that M1-cultured cells produced a higher amount of IL-6, whereas M2- but not M1-cultured cells secreted IL-10 (Additional file 1: Figure S1E and F). Both types of cells did not synthesize a detectable level of either cytokine in the absence of LPS. These data indicate that both phenotypic features and cytokine profiles of cells derived from M1 and M2 conditions were compatible with those of M1 and M2 Mφ. Thus, we applied this protocol in the following experiments.

CCR1 and IL-10 expression by M1 and M2 Mφ differentiated in vitro

Having established the Mφ polarization protocol, we compared CCR1 expression and IL-10 production, both of which are identified as BD susceptible genes, by M1 and M2 Mφ. We found that M2 Mφ showed higher amounts of CCR1 mRNA and protein than M1 Mφ (Fig. 1a and b). Consistently, immunocytochemical analysis confirmed that CD163 and CCR1 were more abundant in M2 Mφ than in M1 Mφ (Fig. 1c).

Fig. 1
figure 1

Comparison of M2 marker expression and function between M1 and M2 macrophages (Mφ) derived from healthy control subjects (HC). C-C chemokine receptor 1 (CCR1) messenger RNA (mRNA) and surface protein expression of M1 and M2 Mφ were detected using (a) real-time PCR and (b) flow cytometry, respectively. c IHC staining showing expression of CD163 and CCR1 in M1 and M2 Mφ (original magnification × 400). d CCR1 single-nucleotide polymorphism (SNP) rs7616215 genotype and expression of CCR1 mRNA and (e) IL10 SNP rs1518111 genotype and IL10 mRNA expression in M1 and M2 Mφ. f Chemotaxis of M1 (red) and M2 Mφ (black) toward macrophage inflammatory protein (MIP)-1α were determined by Transwell migration assay. The results are shown as the migration index. Red horizontal bars indicate median values. P values were determined by Student t test and one-way analysis of variance (**P < 0.01, ***P < 0.001). RQ Relative quantity

Full size image

We next looked at the association between IL10 and CCR1 mRNA expression and their corresponding BD-associated SNP genotypes. We found that BD risk allele was associated with decreased expression of both CCR1 and IL10 mRNA production in polarized Mφ. A significant expression quantitative trait loci (eQTL) effect was found only in M1 Mφ for CCR1 and IL10 for M2 Mφ (Fig. 1d and e). A recent study demonstrated that rs7616215 has a robust eQTL effect on CCR2, but not CCR1, in monocytes [29]. However, the result was not replicated in our polarized Mφ assay (Additional file 1: Figure S2A).

To examine whether the upregulated CCR1 expression is associated with enhanced chemotaxis against CCR1 ligands, we used a Transwell migration assay with gradient density of MIP-1α, a ligand for CCR1. We found that the migration of M1 Mφ into the lower chamber occurred in relatively higher MIP-1α concentrations than M2 Mφ (Fig. 1f). However, the migration of M2 Mφ into the lower chamber was more efficient at low concentrations of MIP-1α than M1 Mφ, whereas the chemotaxis was rather inhibited with higher concentrations of the chemokine (Additional file 1: Figure S3). Similar findings were reported previously in an unrelated study using this assay system [30]. These findings indicate that increased CCR1 expression contributes to sensitive chemotaxis in response to low levels of MIP-1α in M2 Mφ. These results support the notion that BD-associated CCR1 and IL10 loci have the capacity to alter migration and anti-inflammatory cytokine production in polarized Mφ.

M1 and M2 Mφ in patients with BD

To ask whether the CCR1 expression is affected by the disease itself, we compared the frequency of CCR1-positive M1 and M2 Mφ from HC and BD. To carry out this experiment, 21 patients with BD who fulfilled ISG criteria were enrolled. The background characteristics of the patients and HC are shown in Additional file 1: Table S1 and Table S2, respectively. The results showed that CCR1 surface expression of M1 Mφ was significantly increased in BD compared with HC (Fig. 2a), whereas no difference was detected in M2 Mφ (Fig. 2b). No significant difference between BD and HC was observed in CCR1 mRNA expression. The eQTL effects of rs7616215 on CCR1/2 mRNA and protein are shown in Additional file 1: Figure S2. The statistically significant allele-specific expression was seen only in HC.

Fig. 2
figure 2

Comparison of C-C chemokine receptor 1 (CCR1) and interleukin (IL)-10 expression in macrophages (Mφ) derived from between healthy control subjects (HC) and patients with Behçet’s disease (BD). Flow cytometric analysis of CD68+CD163−CCR1+ (M1 Mφ) cells (a) and CD68+CD163+CCR1+ (M2 Mφ) cells (b) from HC and patients with BD. c CCR1 messenger RNA (mRNA) expression in M1 and M2 Mφ from HC and patients with BD. d Supernatant IL-10 concentration of lipopolysaccharide-stimulated Mφ from HC and patients with BD. e IL10 mRNA expression in M1 and M2 Mφ from HC and patients with BD. Red horizontal bars indicate median values. P values were determined by Student’s t test. RQ Relative quantity

Full size image

We confirmed that no statistically significant difference in CCR1 positivity was found between treatment with or without biologics, colchicine, or prednisolone (Additional file 1: Figure S4). We also investigated the number of differentiated Mφ between HC and BD, although no significant difference was observed between the groups (Additional file 1: Figure S5).

IL-10 protein and mRNA expression in M2 Mφ from HC and BD is shown in Fig. 2d and e. IL10 mRNA expression was elevated in BD, whereas IL-10 protein production was comparable between BD and HC. The eQTL effect of rs1518111 on IL-10 protein and mRNA is shown in Additional file 1: Figure S6. Statistically significant allele-specific expression was seen only in HC IL10 mRNA.

M1 and M2 Mφ in skin lesions of BD and systemic sclerosis

GWASs and our in vitro data suggested that GWAS-identified CCR1 SNPs confer significant eQTL effects in polarized M1 Mφ, which may lead to skewed Mφ polarization balance in BD local inflammation. To prove this concept, we performed IHC staining of erythema nodosum, which was pathologically diagnosed as septal panniculitis, from the lower limbs of a treatment-naïve patient with BD. We used skin lesions of SSc as a control, which was recently reported to be M2-dominant [31].

As shown in Fig. 3a, CD68+ cells are predominant over CD163+ cells in skin lesions of patients with BD compared with patients with SSc (Fig. 3b). CCR1 and CD163 double-positive cells were found in the skin lesions of patients with BD (Fig. 3c). These results suggest M1 Mφ-dominant inflammation in BD.

Fig. 3
figure 3

Comparison of M1 and M2 macrophages (Mφ) in Behçet’s disease (BD) and systemic sclerosis (SSc) Mφ, and immunofluorescence assay of dermal tissue of a patient with BD. a IHC staining of erythema nodosum from patients with BD and sclerotic dermis of patients with SSc. Antibodies against CD163 and CCR1 (original magnification × 100 [H&E staining] and × 400 [IHC staining]) were used. b The ratio of CD163+ cells (defined as M2 Mφ) and CD68+ cells (defined as whole Mφ) were independently counted in three high-power fields, and the mean value for each patient was calculated. c Immunofluorescence analysis of CCR1 (green) and CD163 (red) in BD erythema nodosum tissue. Nuclei are stained with 4′,6-diamidino-2-phenylindole (DAPI; blue) (original magnification × 400). Arrowhead indicates CCR1 and CD163 double-positive cells (merged image)

Full size image

Plasticity in human M1 and M2 Mφ

As shown in Additional file 1: Figure S1F, M2 Mφ have the capacity to produce IL-10, which has potent anti-inflammatory effects. Lower IL-10 production is a risk for not only BD but also ulcerative colitis [32] and other inflammatory diseases. IL10R-deficient patients experience oral ulceration and IBD, phenotypes resembling BD [33]. It would be of great benefit for patients with BD and other inflammatory diseases if IL-10 supplementation restored M2 Mφ function at inflammatory sites, leading to a favorable clinical outcome.

We tested whether established M1 Mφ could be converted into M2 Mφ in humans. To this end, the M1 and M2 Mφ that underwent 9-day in vitro polarization by GM-CSF or M-CSF were cultured for an additional 9 days in the presence of the same or other cytokines (Fig. 4a). Expression of CD163, IL6, IL10, and CCR1 mRNA was measured at the end of culture (Fig. 4b–e). We found that treatment with M-CSF, but not with GM-CSF, restored expression of IL10 mRNA with downregulation of IL6 mRNA. On the contrary, IL10 mRNA expression was decreased by GM-CSF in M2 Mφ. Thus, the final expression patterns of CD163, IL6, IL10, and CCR1 mRNA depended on the second cytokine rather than on the first one. The results suggest that Mφ phenotypes are partly but not completely interchangeable between M1 and M2 Mφ, depending on circumstantial factors, including cytokines.

Fig. 4
figure 4

Plasticity of M1 and M2 macrophages (Mφ). a Protocol of plasticity assay in Behçet’s disease (BD) and systemic sclerosis (SSc) Mφ. b–e CD163 (b), IL-6 (c), IL-10 (d), and CCR1 (e) mRNA expression from M1g, M1m, M2g, and M2m cells are shown. Red horizontal bars indicate median values. GM-CSF Granulocyte-macrophage colony-stimulating factor, M-CSF Macrophage colony-stimulating factor, RQ Relative quantity

Full size image

Discussion

In the previous GWASs and subsequent genetic studies, associations of IL10 [4, 6, 14] and CCR1 [5, 34] loci with BD were independently replicated in multiple populations. Therefore, they are now considered bona fide loci involved in the pathogenesis of BD [35], though the pathological role remains uncertain regarding the functional basis.

The present study shows that both IL10 and CCR1 genes were preferentially expressed on M2 Mφ, suggesting that the disease-susceptible SNPs of the genes are responsible for impaired migration of M2 Mφ into the inflammatory lesions and reduced local synthesis of IL-10 in BD. Thus, although IL10 and CCR1 SNPs are independently identified as susceptible loci of BD, it is likely that their pathogenic roles are summarized into the impaired M2 Mφ function in BD.

Anti-inflammatory effects of IL-10 are mediated by HO-1, which was previously shown to be expressed on M2 Mφ preferentially [36, 37]. We have previously shown defective HO-1 synthesis to be associated with excessive expression of Toll-like receptor 4, another disease-susceptible gene product, leading to amplification of inflammation in patients with BD [23, 38]. These findings provided additional circumstantial evidence of impaired M2 Mφ functions in BD.

Although biologics targeting IL-10 would be useful for the treatment of inflammatory diseases, there are no commercially available drugs that directly manipulate IL-10 levels in humans. In animals, enhancing M2 Mφ has been shown to be protective in several SLE models [39, 40]. It is plausible that a treatment strategy could be directed at enhancement of IL-10 production or local accumulation of M2 Mφ into inflammatory lesions, contributing to the improvement of clinical outcomes of BD. TNF inhibitors may lead to a relative enrichment of M2 Mφ by inhibiting M1 Mφ function, because we have previously shown that HO-1 mRNA expression in circulating monocytes is increased during treatment with infliximab in patients with rheumatoid arthritis [41]. Alternatively, apremilast, a phosphodiesterase 4-selective inhibitor for which an international clinical trial for BD is ongoing, stimulates the production of IL-10 and downregulates that of proinflammatory cytokines [42]. These findings suggest that clinical efficacy of these treatments is associated with corrected M1/M2 balance for BD, though direct evidence has not been provided to date.

A significant difference between BD and HC was observed in CCR1 protein expression but not in CCR1 mRNA expression. We could not detect genotype-dependent IL-10 expression differences in BD. Rather, IL10 mRNA expression was higher in patients with BD (Fig. 2e). We posit the following possibilities:

  1. 1.

    Because the disease-protective GG genotype of IL10 SNP rs1518111 and the CC genotype of CCR1 SNP rs7616215 in patients with BD were small, the power to identify mRNA expression differences was limited in BD samples.

  2. 2.

    Effects of disease status or treatments could have affected IL-10 expression.

  3. 3.

    The sample size was too small to identify small expression differences caused by the SNP.

However, because SNPs tag common DNA haplotypes in human populations, data identified in healthy individuals would be applicable in BD pathogenesis. Further IL-10 and CCR1 transcriptional analysis is needed to clarify whether IL-10 and CCR1 expression may be dysregulated in BD.

There has been a discrepancy regarding the eQTL effect of rs7616215 genotype on CCR1/2 expression between this report and a former one [29]. We speculate the following possibilities:

  1. 1.

    The examined cells are different; we evaluated M1 and M2 macrophages, whereas Ishigaki et al. evaluated human peripheral monocytes.

  2. 2.

    The assay used to detect mRNA expression was different; we used real-time PCR, whereas Ishigaki et al. used RNA sequencing.

  3. 3.

    The sample size is too small to identify CCR2 expression differences in our study.

However, in our previous paper [5], we found a similar CCR1 eQTL pattern in human peripheral monocytes in samples from white Americans as well as in publicly available mRNA array data [43]. These data support our hypothesis that rs7616215 affects CCR1 mRNA expression.

We could not evaluate CCR1 genotype dependent migration differences in the present study for the following reasons: (1) 50-ml blood samples were needed to obtain a large-enough M1 or M2 macrophage count for the Transwell migration assay, and (2) owing to large experimental variation of the Transwell migration assay of polarized macrophages, a large sample size would be necessary to detect subtle effects caused by the common SNP. However, as we have previously shown significant migration differences by rs7616215 genotypes in human monocytes [5], similar migration differences may be found in human macrophages as well.

Figure 5 shows our hypothesis based on the present study. M2 Mφ expressing high levels of CCR1 have the advantage of migration to inflammatory lesions, where CCR1 ligands such as MIP-1α are secreted, compared with M1 Mφ. Subsequently, the local inflammation is decreased by M2 Mφ in healthy individuals. However, the inflammatory condition would be persistent in patients with BD because M2 Mφ function is impaired by the genetic predisposition. Local accumulation of M2 Mφ is decreased owing to the reduced CCR1-dependent chemotaxis. Local IL-10 production would also be much less in patients with BD than in HC owing to the reduced number of M2 Mφ in addition to low IL-10-synthesizing capacity. Furthermore, the frequency of CCR1-positive M1 Mφ is rather increased in patients with BD compared with HC, suggesting a more efficient accumulation of M1 Mφ into MIP-1α-enriched inflammatory lesions in BD than in HC. These unexpected findings may be caused by epigenetic or environmental factors [44]. Taken together, both quantitative and functional balance between M1 and M2 Mφ shift toward M1-predominant type in inflammatory lesions, resulting in a vicious cycle of local inflammation. We added our new hypothesis to the previously proposed schema representing the pathogenesis of BD (Additional file 1: Figure S7) [45, 46].

Fig. 5
figure 5

The hypothesis of C-C chemokine receptor 1 (CCR1) and interleukin (IL)-10 function in Behçet’s disease (BD) macrophages. MIP-1α Macrophage inflammatory protein, HC Healthy control subjects

Full size image

Phenotypic plasticity of matured Mφ is an important issue for future study. Our data indicated that Mφ function was modified by M-CSF or GM-CSF at least in vitro. Particularly, we confirmed that in vitro polarized M1 Mφ restored IL-10 synthesis capacity in the presence of M-CSF. Even such partial modification of Mφ function would be beneficial for patients with BD.

This study has some limitations. First, most of the data were obtained from in vitro experiments, which might not fully reflect the in vivo biological events in patients with BD. Second, because biopsies of affected lesions in BD are not routinely done for the diagnosis of BD, only small numbers of skin biopsy specimens could be evaluated. In addition, the timing of skin biopsy in the disease course may influence the balance between M1 and M2 Mφ. Finally, most of the patients with BD were receiving some of the therapeutic agents, which might have affected the results of in vitro culturing. However, the 9-day in vitro polarization protocol may have minimized the influence of the therapeutic agents, as shown in Additional file 1: Figure S4. Nonetheless, our data reveal the difference in CCR1 expression of M1 Mφ between patients with BD and HC.

Conclusions

The present study shows that BD-associated CCR1 and IL10 loci are responsible for defective M2 Mφ, resulting in skewed M1 Mφ polarization in BD. Our data suggest that phenotypic plasticity is partially conserved in matured M1 and M2 Mφ. Strategies to correct the imbalance between M1 and M2 Mφ or to modify Mφ function would be promising for patients with BD in the future.

Abbreviations

BD:

Behçet’s disease

CCR:

C-C chemokine receptor

CD:

Cluster of differentiation

cDNA:

Complementary DNA

DAPI:

4′,6-Diamidino-2-phenylindole

eQTL:

Expression quantitative trait loci

GAPDH:

Glyceraldehyde 3-phosphate dehydrogenase

GM-CSF:

Granulocyte-macrophage colony-stimulating factor

GWAS:

Genome-wide association study

HC:

Healthy control subjects

HO:

Heme oxygenase

IBD:

Inflammatory bowel disease

IgG:

Immunoglobulin G

IL:

Interleukin

ISG:

International Study Group

LPS:

Lipopolysaccharide

M-CSF:

Macrophage colony-stimulating factor

MIP:

Macrophage inflammatory protein

mRNA:

Messenger RNA

Mφ:

Macrophages

PBMC:

Peripheral blood mononuclear cells

SLE:

Systemic lupus erythematosus

SNP:

Single-nucleotide polymorphism

SSc:

Systemic sclerosis

Th:

Helper T cell

TNF:

Tumor necrosis factor

References

  1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med. 1999;341(17):1284–91.

    Article  PubMed  CAS  Google Scholar 

  2. Yazici H, Fresko I, Yurdakul S. Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007;3(3):148–55.

    Article  PubMed  Google Scholar 

  3. Ono S, Aoki K, Sugiura S, Nakayama E, Itakura K. Letter: HL-A5 and Behçet’s disease. Lancet. 1973;2(7842):1383–4.

    Article  Google Scholar 

  4. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42(8):698–702.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 2013;45(2):202–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nat Genet. 2010;42(8):703–6.

    Article  PubMed  CAS  Google Scholar 

  7. Li H, Liu Q, Hou S, Du L, Zhou Q, Zhou Y, et al. TNFAIP3 gene polymorphisms confer risk for Behçet’s disease in a Chinese Han population. Hum Genet. 2013;132(3):293–300.

    Article  PubMed  CAS  Google Scholar 

  8. Xavier JM, Shahram F, Sousa I, Davatchi F, Matos M, Abdollahi BS, et al. FUT2: filling the gap between genes and environment in Behçet’s disease? Ann Rheum Dis. 2015;74(3):618–24.

    Article  PubMed  CAS  Google Scholar 

  9. Kappen JH, Medina-Gomez C, van Hagen PM, Stolk L, Estrada K, Rivadeneira F, et al. Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Behçet disease. PLoS One. 2015;10(3):e0119085.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Takeuchi M, Mizuki N, Meguro A, Ombrello MJ, Kirino Y, Satorius C, et al. Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet’s disease susceptibility. Nat Genet. 2017;49(3):438–43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Kirino Y, Remmers EF. Genetic architectures of seropositive and seronegative rheumatic diseases. Nat Rev Rheumatol. 2015;11(7):401–14.

    Article  PubMed  CAS  Google Scholar 

  12. Aridogan BC, Yildirim M, Baysal V, Inaloz HS, Baz K, Kaya S. Serum levels of IL-4, IL-10, IL-12, IL-13 and IFN-γ in Behçet’s disease. J Dermatol. 2003;30(8):602–7.

    Article  PubMed  CAS  Google Scholar 

  13. Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet’s disease. Arthritis Rheum. 2004;50(7):2291–5.

    Article  PubMed  CAS  Google Scholar 

  14. Wu Z, Zheng W, Xu J, Sun F, Chen H, Li P, et al. IL10 polymorphisms associated with Behçet’s disease in Chinese Han. Hum Immunol. 2014;75(3):271–6.

    Article  PubMed  CAS  Google Scholar 

  15. de Wynter EA, Heyworth CM, Mukaida N, Jaworska E, Weffort-Santos A, Matushima K, et al. CCR1 chemokine receptor expression isolates erythroid from granulocyte-macrophage progenitors. J Leukoc Biol. 2001;70(3):455–60.

    PubMed  CAS  Google Scholar 

  16. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41(1):61–70.

    Article  PubMed  CAS  Google Scholar 

  17. Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, et al. Cytokine production profile in patients with Behçet’s disease treated with infliximab. Cytokine. 2003;24(5):210–8.

    Article  PubMed  CAS  Google Scholar 

  18. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399–416.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A. 2004;101(13):4560–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65(8):3437–46.

    Article  PubMed  CAS  Google Scholar 

  21. Endo N, Tsuboi N, Furuhashi K, Shi Y, Du Q, Abe T, et al. Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis. Nephrol Dial Transplant. 2016;31(12):2023–33.

    Article  PubMed  CAS  Google Scholar 

  22. Anower AK, Shim JA, Choi B, Kwon HJ, Sohn S. The role of classical and alternative macrophages in the immunopathogenesis of herpes simplex virus-induced inflammation in a mouse model. J Dermatol Sci. 2014;73(3):198–208.

    Article  PubMed  CAS  Google Scholar 

  23. Kirino Y, Takeno M, Watanabe R, Murakami S, Kobayashi M, Ideguchi H, et al. Association of reduced heme oxygenase-1 with excessive Toll-like receptor 4 expression in peripheral blood mononuclear cells in Behçet’s disease. Arthritis Res Ther. 2008;10(1):R16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335(8697):1078–80.

    Google Scholar 

  25. Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911–20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Anderson MW, Zhao S, Ai WZ, Tibshirani R, Levy R, Lossos IS, et al. C-C chemokine receptor 1 expression in human hematolymphoid neoplasia. Am J Clin Pathol. 2010;133(3):473–83.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Gordon IO, Freedman RS. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res. 2006;12(5):1515–24.

    Article  PubMed  CAS  Google Scholar 

  28. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–96.

    Article  PubMed  CAS  Google Scholar 

  29. Ishigaki K, Kochi Y, Suzuki A, Tsuchida Y, Tsuchiya H, Sumitomo S, et al. Polygenic burdens on cell-specific pathways underlie the risk of rheumatoid arthritis. Nat Genet. 2017;49(7):1120–5.

    Article  PubMed  CAS  Google Scholar 

  30. Corcione A, Tortolina G, Bonecchi R, Battilana N, Taborelli G, Malavasi F, et al. Chemotaxis of human tonsil B lymphocytes to CC chemokine receptor (CCR) 1, CCR2 and CCR4 ligands is restricted to non-germinal center cells. Int Immunol. 2002;14(8):883–92.

    Article  PubMed  CAS  Google Scholar 

  31. Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther. 2010;12(4):R128.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet. 2008;40(11):1319–23.

    Article  PubMed  CAS  Google Scholar 

  33. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361(21):2033–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Hou S, Xiao X, Li F, Jiang Z, Kijlstra A, Yang P. Two-stage association study in Chinese Han identifies two independent associations in CCR1/CCR3 locus as candidate for Behçet’s disease susceptibility. Hum Genet. 2012;131(12):1841–50.

    Article  PubMed  CAS  Google Scholar 

  35. Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behçet’s disease: a comprehensive review. J Autoimmun. 2015;64:137–48.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med. 2002;8(3):240–6.

    Article  PubMed  CAS  Google Scholar 

  37. Naito Y, Takagi T, Higashimura Y. Heme oxygenase-1 and anti-inflammatory M2 macrophages. Arch Biochem Biophys. 2014;564:83–8.

    Article  PubMed  CAS  Google Scholar 

  38. Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet disease. Proc Natl Acad Sci U S A. 2013;110(20):8134–9.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Han KH, Gonzalez-Quintial R, Peng Y, Baccala R, Theofilopoulos AN, Lerner RA. An agonist antibody that blocks autoimmunity by inducing anti-inflammatory macrophages. FASEB J. 2016;30(2):738–47.

    Article  PubMed  CAS  Google Scholar 

  40. Li F, Yang Y, Zhu X, Huang L, Xu J. Macrophage polarization modulates development of systemic lupus erythematosus. Cell Physiol Biochem. 2015;37(4):1279–88.

    Article  PubMed  CAS  Google Scholar 

  41. Kirino Y, Takeno M, Murakami S, Kobayashi M, Kobayashi H, Miura K, et al. Tumor necrosis factor α acceleration of inflammatory responses by down-regulating heme oxygenase 1 in human peripheral monocytes. Arthritis Rheum. 2007;56(2):464–75.

    Article  PubMed  CAS  Google Scholar 

  42. Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, et al. Apremilast for Behçet’s syndrome—a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510–8.

    Article  PubMed  CAS  Google Scholar 

  43. Zeller T, Wild P, Szymczak S, Rotival M, Schillert A, Castagne R, et al. Genetics and beyond – the transcriptome of human monocytes and disease susceptibility. PLoS One. 2010;5(5):e10693.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Hughes T, Ture-Ozdemir F, Alibaz-Oner F, Coit P, Direskeneli H, Sawalha AH. Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Behcet's disease, Arthritis Rheumatol. 2014;66(6):1648–1658.

  45. Hilhorst M, Shirai T, Berry G, Goronzy JJ, Weyand CM. T cell-macrophage interactions and granuloma formation in vasculitis. Front Immunol. 2014;5:432.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Hirohata S, Kikuchi H. Behçet’s disease. Arthritis Res Ther. 2003;5(3):139–46.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from the Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research (26713036 [to YK], 26461469 [to MT], 26461468 [to RY], and 16K19085 [to IK]), the Yokohama Foundation for Advancement of Medical Science (to YK and RY), the Naito Memorial Foundation (to YK), the Uehara Memorial Foundation (to YK), the Japan Intractable Diseases Research Foundation (to YK and MT), the Japan Rheumatism Foundation (to YK), and the Takeda Science Foundation (to RY). We express our gratitude to Momoko Ohno and Masato Kawashima for their assistance and Tom Kiper for correcting the grammar of this paper.

Funding

This study is supported by grants from the Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research (26713036 [to YK], 26461469 [to MT], 26461468 [to RY], and 16K19085 [to IK]), the Yokohama Foundation for Advancement of Medical Science (to YK and RY), the Naito Memorial Foundation (to YK), the Uehara Memorial Foundation (to YK), the Japan Intractable Diseases Research Foundation (to YK and MT), the Japan Rheumatism Foundation (to YK), and the Takeda Science Foundation (to RY).

Availability of data and materials

The datasets used and analyzed during the present study are available from the corresponding author on reasonable request.

Author information

Authors and Affiliations

  1. Yokohama City University Graduate School of Medicine, Department of Stem Cell and Immune Regulation, Yokohama, Japan

    Hiroto Nakano, Yohei Kirino, Kana Higashitani, Hideto Nagai, Ryusuke Yoshimi & Hideaki Nakajima

  2. Nippon Medical School Graduate School of Medicine, Department of Allergy and Rheumatology, Tokyo, Japan

    Mitsuhiro Takeno

  3. Yokohama City University Graduate School of Medicine, Department of Environmental Immuno-Dermatology, Yokohama, Japan

    Yukie Yamaguchi

  4. Yokohama City University Graduate School of Medicine, Department of Molecular Pathology, Yokohama, Japan

    Ikuma Kato & Ichiro Aoki

Authors
  1. Hiroto Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yohei Kirino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mitsuhiro Takeno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kana Higashitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hideto Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ryusuke Yoshimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yukie Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ikuma Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ichiro Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hideaki Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

H Nakano performed experiments, analyzed data and wrote the manuscript. KH, H Nakajima, YY, and IK performed some experiments. MT, RY, IA, and H Nagai coordinated the research and critically revised the manuscript. YK conceived of the experimental design, analyzed data, and wrote the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yohei Kirino.

Ethics declarations

Ethics approval and consent to participate

The study protocol and genetic analyses were approved by Yokohama City University Ethics Board (A140327015 and B131107009). All of the human samples were used after written informed consent was obtained.

Competing interests

MT serves as an advisor for the apremilast clinical trial for Celgene.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1:

Figure S1. Comparison of phenotypic features and cytokine profiles between M1 and M2 cultured cells. Figure S2. eQTL effect of rs7616215 on CCR2 and CCR1. Figure S3. Detailed results of chemotaxis of M2 Mφ toward various concentrations of MIP-1α. Figure S4. Differences in CCR1 positivity (fluorescence-activated cell sorting) between treatments. a Biologics. b Colchicine. c Prednisolone. Figure S5. The number of differentiated Mφ in vitro in HC and BD. Figure S6. eQTL effect of rs1518111 on IL-10 protein and mRNA. Figure S7. Schema showing our proposed immunological responses in BD. Table S1. Characteristics of patients with BD who participated in the study. Table S2. Characteristics of HC study participants. (DOCX 9663 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakano, H., Kirino, Y., Takeno, M. et al. GWAS-identified CCR1 and IL10 loci contribute to M1 macrophage-predominant inflammation in Behçet’s disease. Arthritis Res Ther 20, 124 (2018). https://doi.org/10.1186/s13075-018-1613-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13075-018-1613-0

Keywords

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us